115 related articles for article (PubMed ID: 6991101)
1. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
Westerberg H
Cancer Treat Rep; 1980 Jan; 64(1):117-21. PubMed ID: 6991101
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
[TBL] [Abstract][Full Text] [Related]
3. Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen.
Fornander T; Rutqvist LE; Glas U
Cancer Treat Rep; 1987; 71(7-8):685-8. PubMed ID: 3300966
[TBL] [Abstract][Full Text] [Related]
4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
5. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogen treatment of breast cancer: an overview.
Pearson OH; Manni A; Arafah BM
Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
8. [Internal endocrine therapy of breast cancer].
Yoshida M; Miura S
Gan To Kagaku Ryoho; 1984 May; 11(5):989-98. PubMed ID: 6372698
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
10. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
11. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer.
Falkson G; Gelman RS; Tormey DC; Taylor SG; Falkson HC
Cancer Treat Rep; 1985; 69(7-8):755-60. PubMed ID: 4016786
[TBL] [Abstract][Full Text] [Related]
13. The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer.
Stewart HJ; Forrest AP; Gunn JM; Hamilton T; Langlands AO; McFadyen IJ; Roberts MM
Eur J Cancer (1965); 1980; Suppl 1():83-8. PubMed ID: 7032945
[No Abstract] [Full Text] [Related]
14. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
[TBL] [Abstract][Full Text] [Related]
15. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer--a randomized study.
Swain SM; Steinberg SM; Bagley C; Lippman ME
Breast Cancer Res Treat; 1988 Sep; 12(1):51-7. PubMed ID: 3058238
[TBL] [Abstract][Full Text] [Related]
17. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
[TBL] [Abstract][Full Text] [Related]
19. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.
Tormey DC; Lippman ME; Edwards BK; Cassidy JG
Ann Intern Med; 1983 Feb; 98(2):139-44. PubMed ID: 6824247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
